**: The home of the instrument, unauthorized shall not **, and 24 hours later**.
The home of the equipment learned that Wu Rongguang, the founder of the well-known sports brand Hongxing Erke and the chairman of Hongxing Erke Investment Company, recently attended the brand listing conference called Duoying (Xiamen) Biotechnology***, hereinafter referred to as "Duoying Biotechnology").
It is understood that Duoying Biotechnology is a high-tech enterprise focusing on synthetic biology, and its product strength lies in the core patented ingredient recombinant collagen. At this press conference, it launched two new brands, "Duoying" and "Yibentong", a brand focusing on recombinant collagen.
It is worth mentioning that, according to Tianyancha data, the controlling shareholder of Duoying Biotechnology is Wu Rongguang, and the company also controls two companies, "Yibentong (Xiamen) Biotechnology" and "Duoying (Xiamen) Beauty". In addition, it has also reached a strategic cooperation with the world-renowned recombinant collagen upstream business polysource biology.
"Hongxing Erke founder" absolute holding, hand in hand with the upstream boss
According to public information, Duoying Biotech, founded in June 2023, is a high-tech enterprise focusing on synthetic biology, integrating cosmetics research and development, production and sales. It has its own brands "Duoying" and "Emputone", covering the beauty fields such as functional skin care and medical art aftercare.
Its product strength lies in the core patented ingredient recombinant collagen, based on its important effect on the human body and modern biosynthesis technology, providing a full range of solutions from the source, so that the best barrier can be repaired more efficiently and deeply.
Wu Rongguang is absolutely controlled
It should be said that according to Tianyancha data, the company is 80% owned by Wu Rongguang, the founder of Hongxing Erke and chairman of Hongxing Erke Investment Company, which is an absolute controlling stake. The company also holds two companies, "Yibentong (Xiamen) Biotechnology*** and "Duoying (Xiamen) Beauty***".
At the brand launch and product launch conference on December 12, 2023, Duoying Biotechnology grandly launched two new brands, "Duoying" and "Yibentong", a brand focusing on recombinant collagen. At the same time, as a company invested by Hongxing Erke, at this press conference, it successfully released a series of recombinant collagen beauty care products with Juyuan Biotech, including recombinant type III humanized collagen solution, dressings, repair gels, etc.
Hand in hand with the upstream boss
In addition, it has also reached a strategic cooperation with the world-renowned recombinant collagen upstream business polysource biology. It is reported that it was established in 2015 by the world's largest nutrition provider Aland Group (Aland), the team of Professor Yang Shulin, the inventor of recombinant human collagen (RHC) technology, and Nanjing University of Science and Technology (NJUST).
Focusing on the research and development of recombinant collagen for more than 20 years, it has taken the lead in realizing the whole industrial chain layout of gene design, strain construction, industrialization design, tonnage capacity scale-up, downstream application research and development, downstream product safety and efficacy testing based on recombinant functional proteins. It mainly produces and develops recombinant humanized collagen related skin care products, and the products are exported to more than 80 countries and regions such as Europe, North America, Japan, and the Middle East.
As a leading recombinant collagen industry chain company in the industry, Juyuan Biotech has reached long-term strategic cooperation with many well-known enterprises at home and abroad. At the same time, it is also the world's largest collagen raw material manufacturer, and the only collagen raw material supplier in China that has obtained the US FDA certification, and the world's largest recombinant collagen expression.
In recent years, Hongxing Erke Investment has also been actively deploying in this field. Under the high degree of compatibility of the development strategies of the two parties, Juyuan Biotech and Hongxing Erke Investment Company's brand Yibentong have reached close cooperation in the upstream and downstream of the industrial chain to promote the rapid development of the domestic functional skin care industry.
In this cooperation, the two parties will rely on the outstanding industry position and excellent academic attainments of Juyuan Biotech in the field of synthetic biology, give full play to the advantages of the upstream and downstream first-chain resources of Juyuan Biotech, and combine the experience advantages and market insights of Hongxing Erke Investment Company in the field of biomedicine to jointly develop a variety of recombinant collagen products used in different fields to create a high-end first-class care brand leading the industry.
At present, the two parties have in-depth cooperation on a series of recombinant collagen beauty care products, such as recombinant type III humanized collagen solution, patch dressings, repair gels, ** gels, etc.
Hongxing Erke medical layout
In fact, in the medical field, Hongxing Erke can be said to have been laid out for a long time, the company's founder Wu Rongguang founded Hongxing Erke (Xiamen) Investment Management in 2006, the investment company is mainly engaged in equity investment and financial services in the field of biomedicine and health.
Equity investment
Among them, in terms of equity investment, Hongxing Erke Investment focuses on the field of big health, mainly focusing on the layout of the biomedical and medical device industries with innovative breakthrough significance, and has successively invested in dozens of innovative biomedical companies, medical service projects and well-known biopharmaceuticals at home and abroad with development potential, and has maintained in-depth cooperation and interaction with many top pharmaceutical companies and enterprises at home and abroad.
Invested in Hillhouse
Among them, 1031 were invested in 2014250,000 yuan, in 2016 invested 30 million yuan in Lanchi Venture Capital, and also invested many times in the headquarters of Hongxing Erke Group Building, Siming District, Xiamen, now known as Jufeng Investment focusing on the medical field. On May 27, 2021, Hongxing Erke (Xiamen) Investment Management Co., Ltd. added a new foreign investment, and the investment company is Suzhou Hillhouse Qirui Medical and Health Industry Investment Partnership (Limited Partnership).
Invest in Deyun Kangrui - Single-Cell Sequencing
On November 2, 2021, it was reported that Rongsheng (Xiamen) Investment, a subsidiary of Hongxing Erke Investment Group, also participated in Deyun Kangrui's 1RMB 300 million Series A financing. The company is a single-cell and spatial multi-omics technology platform enterprise, the company focuses on tapping the huge potential in the fields of tumor precision medicine, eugenics, and drug discovery, and is committed to promoting precision medicine to move towards the era of single-cell and spatial omics, helping life science and clinical medicine, and contributing Chinese wisdom to the cause of human health.
As a leading enterprise in the field of single-cell spatial omics in China, it took the lead in launching a new RNA in situ sequencing technology with subcellular resolution for spatial omics, and quickly commercialized the single-molecule RNA in situ hybridization technology and obtained medical device filing, promoting the transformation and implementation of a number of clinical-grade spatial omics products.
Hongxing Erke (Xiamen) Biotechnology was established
In June 2023, Hongxing Erke (Xiamen) Biotechnology Co., Ltd. was also established, with a registered capital of 10 million yuan, and its business scope includes medical research and experimental development, science and technology intermediary services, wholesale of protective equipment for medical personnel, retail of protective equipment for medical personnel, etc. Shareholder information shows that the company is owned by Hongxing Erke (Xiamen) Investment Management *** Zhao Suxia respectively held shares%.
Medical financial leasing
In terms of financial services, the company's Chuangxin financial leasing company is committed to promoting the development of China's medical industry, focusing on the financial leasing business of medical devices, and has established close cooperation with hundreds of well-known hospitals, professional medical institutions and major medical industry associations across the country, and has a high reputation, strong competitiveness and good reputation in the industry.
The 100 billion track of the future
In recent years, the application demand for collagen products, a popular field of synthetic biology, has continued to grow, and the penetration rate of recombinant collagen has increased rapidly, ushering in rapid development. According to data from Forrest & Sullivan, the market size of recombinant collagen products reached 10.8 billion yuan in 2021 and is expected to grow to 108.3 billion yuan by 2027, with a compound annual growth rate of 424%。
Although the recombinant collagen industry has developed rapidly in recent years, there is still a fairly high technical threshold in this field. At present, Xi'an Juzi Biogene Technology Co., Ltd., Shanxi Jinbo Biopharmaceutical Co., Ltd., Jiangsu Chuangjian Medical Technology Co., Ltd., Jiangsu Jiangshan Juyuan Biotechnology Co., Ltd. (Juyuan Bio) are in the first echelon of the domestic market. It is understood that the products of these 4 companies account for 98% of the domestic market.
Giant creatures
Founded in 2000, relying on the three major technical systems of biomanufacturing of recombinant collagen, biomanufacturing of highly active natural products, and R&D and preparation of new biomedical materials, Juzi Biotech focuses on the three major health industry directions of advanced medicine, medical devices, preventive medicine and nutritional medicine, and is mainly engaged in business segments such as biomaterials, biomedicine, nutrition and health, advanced medicine, beauty and skin care.
On November 4, 2022, the company was successfully listed on the main board of the Hong Kong Stock Exchange, becoming the "first recombinant collagen stock". In March this year, Juzi Biotech released its first financial report since its listing: revenue of 236.4 billion yuan, a year-on-year increase of 52%;Net profit also exceeded 10 with an increase of 21%.0.2 billion yuan. Among them, the main brand Kefumei achieved revenue of 1.6 billion yuan.
NeoHealth
Founded in 2015, Neo-Health is committed to the mission of recombinant collagen biomaterials, focusing on the R&D and production of recombinant collagen-based biomaterials. It is the first in the country to realize the green preparation and industrial production of recombinant collagen, and its output of recombinant collagen raw materials ranks among the top in China. With the high standards of medical devices, it has covered the application scenarios of recombinant collagen in many fields such as medicine, tissue engineering, food and cosmetics, and has formed three major business segments: biological raw materials, medical terminals, and ODM.
In August 2022, it completed its first round of financing of nearly 200 million yuan, led by Shiseido's first special investment in China. This year, it has completed more than 200 million yuan in Series B financing, co-led by L Catterton, the world's largest full-cycle consumer investment, and CLSA, a subsidiary of CITIC**.
Jinbo Biotech
Founded in 2008, Jinbo Biotech is a leading and representative enterprise in China that has realized the industrialization of recombinant humanized collagen. On June 29, 2021, its self-developed Class III medical device "Recombinant Humanized Collagen Lyophilized Fiber" was approved for marketing by the National Medical Products Administration. This product is the first medical device independently developed in China using a new type of biomaterial - recombinant humanized collagen.
On July 20, 2023, Jinbo Biotech (**832982) was listed on the Beijing ** Stock Exchange, becoming the "first recombinant collagen stock" on the Beijing Stock Exchange.
Bloomage Biotech
Founded in 2000, Bloomage Biotech started with the production and R&D of hyaluronic acid (hyaluronic acid) raw materials. The company started with the production of hyaluronic acid raw materials, and in 2007 became the world's largest hyaluronic acid manufacturer. According to Frost & Sullivan data, in 2021, Bloomage Biotech's sales of hyaluronic acid raw materials accounted for 44% of global sales.
In April 2022, Bloomage Biotech acquired Beijing Yierkang to lay out collagen, and in September 2023, it was revealed that 7 8 kinds of collagen under development have realized the preparation of macromolecular recombinant collagen, and completed the listing of recombinant human collagen raw materials in August.
In recent years, with the rising market demand, as well as the continuous upgrading of recombinant collagen technology, coupled with the continuous bets of capital from all parties on this track, the market potential is huge. Hongxing Erke has been in the medical field for many years, and the launch of recombinant collagen, and hand in hand with the upstream boss of the industry, is expected to quickly take root and usher in a new development pattern. In this regard, the home of equipment will continue to pay attention.